CREXONT
Generic Name/API: carbidopa and levodopa
Manufacturer: Amneal Specialty, a division of Amneal Pharmaceuticals LLC
Dosage Forms & Strength & Pack Size:
Extended-Release Capsules: Carbidopa and Levodopa 35 mg / 140 mg, 52.5 mg / 210 mg, 70 mg / 280 mg, 87. 5 mg / 350 mg
Storage:
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in a tightly closed container, protected from light and moisture.
Dispense in a tightly closed, light-resistant container.
CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.
Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.
Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.
CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery until you know how CREXONT affects you.
The most common side effects that may occur with CREXONT are nausea and anxiety.
It is important to avoid sudden discontinuation or rapid dose reduction of CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.
You may take CREXONT with or without food, but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.
Swallow CREXONT whole. Do not chew, divide, or crush the capsules.
Do not take CREXONT with alcohol.
Tell your healthcare provider if you:
- Have any heart conditions, especially if you have had a heart attack or irregular heartbeats
- Experience hallucinations or abnormal thoughts and behaviors
- Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges
- Have thoughts of suicide or have attempted suicide
- Have abnormal involuntary movements that appear or get worse during treatment
- Have ever had a peptic ulcer or glaucoma
- Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm
- Are breastfeeding during therapy
*The contents of this site are for reference only. We do not offer drug procurement service. All information must not be used for any commercial purpose.
